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ABSTRACT
Inflammatory bowel disease (IBD) comprising Crohn’s disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U) may 
appear at any age. As such, IBD commonly affects young patients in their reproductive age. Rate of voluntary childlessness 
among women with IBD far exceed that of the general population, as patients with IBD fear not only the effect of pregnancy 
on the course of inflammatory bowel disease, but also the increased risk of the offspring developing the disease, adverse 
pregnancy outcomes, the effect IBD treatment may have on the health and development of the infant or the risk of relapse 
during pregnancy and the influence of lactation on child development and disease course. This article aims at improving 
pre-conception counseling of patients with inflammatory bowel disease.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a group of chronic 
inflammatory diseases of the gastrointestinal tract including 
ulcerative colitis (UC), Crohn’s disease (CD), and non-specific 
inflammatory bowel disease.
The incidence of ulcerative colitis among women 
is 9.8/100,000 with a peak onset at age 25 to 34 years. 
The incidence of Crohn’s disease among women is about 
5.0/100,000 with a peak onset at age 15 to 24 [1], which 
means that the disease affects women mostly in childbear-
ing age.
Ulcerative colitis is an inflammatory disease of the colon, 
which starts in the rectum and continues proximally up the 
colon. In about one-fifth to one-third of cases, the entire co-
lon is affected. The inflammatory process affects the mucous 
membrane only. The disease manifests itself by diarrhea 
mixed with blood and mucus, abdominal cramping, painful 
urge for bowel movements and low grade fever. The clini-
cal course includes periods of exacerbation and remission.
Crohn’s disease is in turn a segmental inflammation of 
the digestive tract, which may affect any part of the diges-
tive tract but is most often located in the terminal ileum and 
proximal colon. The inflammatory process is transmural — it 
affects all layers of the intestinal wall. Clinical signs include 
abdominal pain, diarrhea (usually without blood), and bloat-
ing. Abdominal pain occurs most often in the right lower 
quadrant and may be accompanied by a low grade fever. 
The disease is characterized by periods of clinical exacerba-
tion and remission.
Women who experience inflammatory bowel disease 
are often concerned about its possible effects on fertility 
and pregnancy, as well as the inheritance of intestinal dis-
ease or developmental defects as side effects of treatment. 
IBD patients are more likely than the general population to 
choose to remain childless [2].
INFLUENCE ON FERTILITY
IBD treatment does not affect fertility. Even though as 
many as 42.7% of women with non-specific intestinal in-
flammation are concerned about infertility according to 
Mountifield [3], IBD patients in remission who have not 
undergone pelvic surgery have comparable fertility to that 
of the general population [2, 4, 5]. Fertility slightly decreases 
in patients during exacerbation or in patients after surgery 
involving pelvic inlet like J-pouch ileo-anal anastomosis. The 
fertility maybe impaired as consequence of tubal adhesions, 
hydrosalpinx, dysfunction of fimbriae, or fallopian tube ob-
struction. The adjusted fertility rate ratio for colitis ulcerosa 
is 0.92 (95% CI 0.86–1.00) while it is 0.87 (95% CI 0.82–0.94) 
for Crohn’s disease [6]. Lower fertility in CD may be attrib-
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uted to inflammation of the fallopian tubes and ovaries and 
dyspareunia in cases where the disease affects the perianal 
area [2]. Şenateş et al. evaluated the ovarian reserve indica-
tor in women of childbearing age with CD and showed that 
levels of anti-Müllerian hormone in the serum of Crohn’s 
disease patients was lower than in the control group and 
its concentration is negatively correlated with the disease 
activity [7].
INFLUENCE OF PREGNANCY ON THE COURSE 
OF INFLAMMATORY BOWEL DISEASES
If conception occurs during remission, the risk of relapse 
does not change. Therefore, patients should be advised to 
become pregnant at a time of quiescent disease. In con-
trast, if fertilization occurs during a period of exacerbation, 
there is a risk of persistent activity or higher rates of relapse 
during pregnancy [5]. Patients with UC are more likely to 
develop relapse during pregnancy than patients with CD, 
regardless of age, nicotine use, pre-existing disease activ-
ity, previous IBD-associated surgery, immunosuppressive 
therapy, or TNF therapy [8]. No difference in the course of 
Crohn’s disease was observed between non-pregnant and 
pregnant women, both during and after childbirth. Risk 
factors for continuous CD activity during pregnancy are 
immunosuppressive therapy and longer history of illness. In 
contrast, ulcerative colitis exacerbations are more likely to 
occur in pregnant patients (both during pregnancy and 
after delivery) than in non-pregnant patients. Relapse may 
occur most often during the first and second trimesters of 
pregnancy [9]. Overall, pregnancy has a positive effect on 
the course of IBD. As the birth rate increases, the need for 
surgical intervention is reduced. In addition, patients with 
a history of pregnancy less frequently require resection of 
the intestine while the interval between operations may be 
longer than for those who have not been pregnant [10]. Over 
a 10-year observational study, Riis et al. reported a reduction 
in rate of exacerbations of CU and CD in the years following 
pregnancy [11].
INFLUENCE ON THE COURSE OF PREGNANCY
Women suffering from inflammatory bowel disease have 
an increased risk of adverse pregnancy outcomes. IBD is 
associated with premature delivery, low birth weight, and 
small for gestational age birth. An increased rate of both 
elective and emergency cesarean sections is also observed 
[12, 13]. An important risk factor for complications during 
pregnancy is the activity of inflammatory bowel disease at 
the time of conception and during pregnancy [14]. Previous 
infertility treatment increases the risk of miscarriage. History 
of intestinal surgery is an independent risk factor for low 
birth weight or cesarean delivery [15]. Mahadevan et al. per-
formed a cohort study comparing obstetric outcomes in IBD 
and IBD-free patients. The proportion of live births was 60% 
in patients with IBD and 68% in patients without intestinal 
inflammatory disease. Miscarriages occurred more often in 
the IBD group (in 23% of cases versus 17% for the control 
group), as did adverse pregnancy outcomes such as low 
birth weight, premature birth and stillbirths (25% vs. 19%). 
The risk of miscarriage increases in IBD patients who have 
undergone bowel surgery. Pregnancy complications such 
as placental abruption, chorioamnionitis, premature rup-
ture of membranes, preeclampsia, eclampsia, fetal distress, 
infection, maternal blood transfusion, placenta previa and 
urine group B streptococcus infection were more common 
in patients with IBD (25% vs. 16%). There was no statistically 
significant difference between the studied groups in terms 
of adverse neonatal events such as the need for intensive 
neonatal care or newborn death (10% vs. 7%) [16]. 
Similarly, Lin et al. showed a higher premature birth 
rate (11.73% vs. 6.25%) and a lower neonatal birth weight 
(12.76% vs. 5.55%) in mothers with colitis ulcerosa as com-
pared to those without the disease [17]. Stephansson et 
al. evaluated the impact of ulcerative colitis on pregnancy 
and found the risk of premature delivery, caesarean sec-
tion, neonatal death and low birth weight to be increased. 
The risk of pregnancy complications was higher in women 
who had undergone CD-related surgery or had a history of 
hospitalization. The authors did not report an increased risk 
of congenital abnormalities in the fetus [18].
Morales et al. studied the effects of CD on the course 
of pregnancy and reported that the disease exacerbation 
was associated with an increased risk of premature labor, 
while conception during exacerbation was associated with 
an increased risk of miscarriage. The relapse rate during 
pregnancy was comparable to that of the non-pregnant 
CD population [19]. Similarly, Stephansson study found 
similar results showing an increased risk of premature labor 
and caesarean section, as well as a slightly increased risk of 
small for gestational age birth. The authors did not report 
an increase in the risk of preeclampsia, low 5-minute Apgar 
score, stillbirth or congenital malformations [20].
MODE OF DELIVERY
The mode of delivery should take into account obstetric 
indications primarily. The gastroenterologist or colorectal 
surgeon should help in assessing the impact of postpartum 
sphincter/pelvic floor dysfunction on current and future 
bowel function. A caesarean section is recommended for 
patients with active disease localized in the perineal area or 
involving the rectum [2]. Episiotomy, if possible, should be 
avoided since it often leads to development of the disease 
in the perineal area. Yet, it is preferable to uncontrolled 
rupture of tissues [21]. Compared to patients delivering by 
caesarean section, the risk of developing the disease de novo 
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in the perineal area after vaginal birth does not increase. 
The disease progression is also less frequent in patients 
who have had previously a localized disease in the perineal 
area and gave birth vaginally [22]. Interestingly, in a study 
of Norton et al. based on a sample of 2178 patients no cor-
relation between vaginal birth and fecal incontinence was 
found [23]. The presence of ileal pouch-anal anastomosis 
remains a relative indication for caesarean section [24]. If not 
contraindicated for other reasons, patients with colostomy 
or ileostomy may deliver vaginally.
HEREDITY
The strongest predictor of developing IBD is family his-
tory. If one parent is affected, the risk of IBD development in 
offspring is 1.6% for UC and 5.2% for CD. If both parents are 
diagnosed with IBD, the lifetime risk of developing the dis-
ease in offspring is estimated at 36% [16]. In case of Crohn’s 
disease, the risk increase is significant if the affected parent 
is the mother and the offspring is female [25].
CONGENITAL MALFORMATIONS
The risk of congenital abnormalities in the offspring of 
women suffering from inflammatory bowel disease is the 
same as in the general population [15, 18, 20]. In the afore-
mentioned Mahadevan study, the authors did not observe 
a difference in the congenital malformation rate between 
women with colitis ulcerosa and Crohn’s disease [16]. Among 
the drugs that may be used to treat IBD, methotrexate and tha-
lidomide are teratogenic and absolutely contraindicated dur-
ing pregnancy. When it comes to the safety of thiopurine and 
corticosteroid therapy during the first trimester, the results 
remain ambiguous [2]. Ban et al. analyzed the incidence of 
congenital anomalies in children born in the United Kingdom 
between 1990 and 2010 and showed that maternal inflam-
matory bowel disease and related therapies did not increase 
the risk of serious congenital abnormalities [26]. Similarly, the 
study of Wozniak et al. on Polish population found no impact 
of IBD on the frequency of congenital anomalies [27].
POSTPARTUM PERIOD
Discontinuing medication may lead to exacerbation of 
the disease. The risk of recurrence in CD patients on main-
tenance therapy is not increased during the postpartum 
period, although it may increase in women with ulcerative 
colitis. UC exacerbation usually occurs within 3 months 
after delivery [5]. 71% of CD patients and 60% of UC pa-
tients remain in remission during the postpartum period, 
compared to 78% and 81% of patients in the control group, 
respectively. For CD patients, more than five years history 
of disease is a risk factor for a recurrence in the postpartum 
period [9]. After the pregnancy, function of J-Pouch remains 
unchanged [24].
LACTATION
The percentage of women with inflammatory bowel 
disease who breast-feed varies from 44.2% to 83.3% [28, 
29]. Breastfeeding is not associated with increased risk 
of disease exacerbation. On the contrary, it may protect 
against relapse in the year following birth, suggested by 
some studies [28, 30]. The risk of relapse in the first year 
after birth for breastfeeding mothers was 26% versus 29.4% 
for non-breastfeeding mothers with CD and 29.2% versus 
44.4% for UC patients, respectively [28]. There are some 
premises that breast-feeding can be protective with respect 
to early-onset IBD in the offspring [30].
TREATMENT
It is usually the gastroenterologists that treat IBD. Basic 
information on treatment during pregnancy and postpar-
tum period is summarized in Tables 1 and 2 [30–36]. Sul-
fasalazine treatment affects folate absorption, therefore 
patients taking sulfasalazine are advised to supplement 
higher doses of folic acid (2 mg/day).
SUMMARY
Inflammatory bowel disease affects a large group of 
women of childbearing age. Patients expect guidelines from 
gynecologists on how to prepare themselves for pregnancy, 
as well as information on whether the disease affects fertil-
ity, the course of pregnancy, whether there is a risk of con-
genital defects associated with inflammation of the bowel 
or treatment thereof, or whether children may inherit the 
disease. Additionally, information on the influence of preg-
nancy and lactation on the course of the disease is essential 
for making fully conscious decisions regarding pregnancy 
and lactation. Access to factual information reduces the 
concerns of patients, reducing the proportion of voluntary 
childless patients.
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Table 1. Therapy during pregnancy
Drugs Use in pregnancy Influence on pregnancy
5-ASA
Mesalamine
Category B
Possible to apply
Low risk 
Does not increase the risk of stillbirth, congenital anomalies, preterm 
delivery, spontaneous abortion or low birth weight
Asacol
(formulations containing 
dibutyl phthalate)
Category C 
Possible to apply 
Low risk 
In animal studies, it causes urinary tract and skeletal system defects 
Recommended to change to mesalamine
Sulfsalazine
Category B 
Possible to apply 
Low risk 
Crosses placental barrier
Inhibits the absorption and metabolism of folic acid
Supplementation up to 2 mg per day of folic acid is recommended during 
preconception period and pregnancy to prevent neural tube defects
Antibiotics
Metronidazole
Category B 
Do not use in the first trimester 
Low risk with short term use
Crosses placental barrier
Single reports of teratogenicity, yet unconfirmed in studies both in 
humans and animals
Ciprofloxacin
Category C
Do not use in the first trimester 
Low risk with short term use
Crosses the placenta
In animal studies it affects bones and cartilage causing potentially arthritis
Unconfirmed in human studies
Corticosteroids
Prednisolone
Category C 
Recommended low doses 
Low risk 
Crosses the placenta
Increased risk of SGA, gestational diabetes, early neonatal infection
Single reports of increased incidence of cleft palate, ultimately unconfirmed
Budesonide
Category B/C 
Recommended low doses 
Low risk 
Crosses the placenta
High first-pass metabolism and less side effects
Immunomodulators
Thiopurines
Category D 
It is not recommended to start treatment 
during pregnancy because of side effects 
such as pancreatitis or leukopenia 
Low risk
Single reports of an increased incidence of preterm delivery and 
congenital ventricular and atrial septal defects
Cyclosporine Category C Low risk
Crosses the placenta
Possible toxic effects
Tacrolimus Category C Low risk 
Crosses the placenta
May cause hyperkalemia and renal dysfunctions
Methotrexate
Category X 
Contraindicated
Stop optimally 3 months before fertilization 
in men and 6 months in female 
Crosses the placenta
Teratogenic effects
May lead to fetal death
Anti-TNF agents
They may cause decreased immunity, therefore live vaccines should be avoided during the first 6–12 months of life of the newborn  
exposed in utero
Adalimumab
Category B
Recommended to stop in third trimester
Low risk 
Crosses the placenta
Does not increase the risk of birth defects, premature births, stillbirths, 
miscarriages or SGA
Certolizumab
Category B 
Can continue during pregnancy 
Low risk 
Minimally crosses the placenta
Does not increase the risk of premature labor or neonatal infection
Infliximab
Category B 
Recommended to stop in third trimester 
Low risk 
Crosses the placenta
Does not increase the risk of preterm delivery or neonatal infection
Golimumab
Category B 
Recommended to stop in third trimester 
Low risk 
Crosses the placenta
→
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Table 1 (cont.). Therapy during pregnancy
Drugs Use in pregnancy Influence on pregnancy
Anti-integrins
Natalizumab
Category C 
Limited human data
Recommended to stop 3 months before 
pregnancy
Possible placental transfer
Increases the risk of spontaneous abortion
Vedolizumab Category BLimited human data Possible placental transfer
Anti-IL-12/23 drugs
Ustekinumab Limited human data 
Table 2. Therapy during lactation
Drugs Influence on lactation Additional impact
5-ASA
Increases levels of free bilirubin, potentially leading to kernicterus 
Mesalamine Low risk Single cases of neonatal diarrhea 
Asacol Low risk 
Sulfsalazine Low risk 
Antibiotics
Metronidazole Avoid prolonged course of treatment Breastfeeding after 12–24 h Potential toxicity in the infant due to prolonged course of treatment
Ciprofloxacin Avoid prolonged course of treatment Breastfeeding after 48 h Prolonged course of treatment may result in neonatal arthropathies
Corticosteroids
Prednisolone Low riskBreastfeeding after 4 h
Budesonide Low risk 
Immunomodulators
Thiopurines Low risk Breastfeeding after 4 h
Cyclosporine Contraindicated High concentration in breast milk
Potential immunosuppressive effect 
Toxicity 
Tacrolimus Low risk Single reports on safety in use
Methotrexate Contraindicated High concentration in breast milk Toxicity 
Anti-TNF drugs Limited data Low concentrations in breast milk and poor absorption lead to  subtherapeutic concentrations in the neonate’s blood 
Adalimumab Low risk 
Certolizumab Low risk Undetectable in breast milk 
Infliximab Low risk 
Golimumab Limited data, low risk 
Anti-integrins
Natalizumab Limited data 
Vedolizumab Limited data 
Anti-IL-12/23 drugs
Ustekinumab Limited data 
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